Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

Inclusion Criteria:

Written informed consent
Stable psoriasis for at least 6 months prior to screening
Chronic pruritus of the psoriasis plaques at least 6 weeks prior to screening
At least moderate baseline overall itch associated with psoriatic plaques
Willing and able to undergo a 4-week run-in with calcipotriene ointment dosing and remain on this stable regimen throughout the study
Mild or moderate psoriasis at screening and baseline
Subject's plaques are amenable to treatment with a topical medication
Willing and able to discontinue all other topical products to treat psoriasis and/or itch, including topical steroids
Willing and able to avoid prolonged exposure of the designated treatment plaques to ultraviolet (UV) radiation (natural and artificial) for the duration of the study
Women of childbearing potential must have a negative pregnancy test and must agree to use highly effective methods of contraception during the study
Men who engage in sexual activity that can result in fathering children must agree to use highly effective forms of contraception during the study

Exclusion Criteria:

Underlying conditions other than psoriasis that, in the opinion of the investigator, currently cause or influence pruritus of the overall skin
Current or past history of hypercalcemia, Vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders
Thyroid abnormalities that, in the opinion of the investigator, are clinically relevant and may affect assessments
Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis
Subjects with a clinical diagnosis of bacterial infection of the skin
Subjects who have previously failed treatment with or failed to tolerate treatment with calcipotriene
Known hypersensitivity to SNA-120 (pegcantratinib), calcipotriene, the study treatment excipients, and /or polyethylene glycol (PEG), or a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation
Currently enrolled in an investigational drug or device study or has used an investigational drug or an investigational device treatment within 30 days or 5 half-lives of investigational drug (whichever is longer) of baseline
Women who are pregnant or lactating, or are planning to become pregnant during the study
Subjects previously participating in any SNA-120 (and/or CT327 or pegcantratinib) clinical studies